Delegates in Geneva are sharply divided over whether e-cigarettes and other nicotine products can help smokers quit or pose new public-health dangers. More than 1,400 participants are debating revisions to the World Health Organization’s tobacco control treaty amid concerns about a continuing global tobacco epidemic: roughly 1.2 billion people still use tobacco, with about 80% living in low- and middle-income countries.
New nicotine delivery systems — including e-cigarettes, heated tobacco devices and nicotine pouches — have triggered two conflicting responses. Some public-health authorities warn these products create fresh risks and are being marketed in ways that attract non-smoking youth. Others, including some clinicians and harm-reduction advocates, argue that for entrenched smokers the alternatives may reduce exposure to the toxins created by burning tobacco and could help people stop smoking combustible cigarettes.
The WHO has taken a firm stance against promoting e-cigarettes as quit aids. In a recent position statement the agency warned that industry actors are co-opting “harm reduction” language to sell products that lack proven net public-health benefit, and it cited mounting evidence of harm. WHO’s director-general, Tedros Adhanom Ghebreyesus, and agency officials have pointed to industry profit motives and high youth uptake — an estimated 15 million young people worldwide — as reasons for strict regulation. They emphasize that flavors, packaging and marketing risk creating a new generation addicted to nicotine.
Medical organizations have echoed those cautions. The International Pediatric Association, writing in Pediatrics, linked e-cigarette use to cardiovascular, metabolic, respiratory and oral harms and to cancer, and warned that people who both vape and smoke (“dual users”) may face higher risks than cigarette-only smokers. Critics argue that a surge in youth vaping could undermine decades of progress in reducing smoking and tobacco-related disease.
On the other side, proponents of harm reduction say absolute bans or blanket condemnations oversimplify nicotine addiction and ignore potential benefits for current smokers. Dr. Derek Yach, a veteran tobacco-control advocate who was involved in drafting the original WHO tobacco treaty, argues that the old “quit or die” messaging did not adequately address addiction and that noncombustible nicotine products could reduce exposure to the carcinogens caused by combustion. Yach’s public support for alternatives and his leadership at a foundation once funded by the tobacco industry have made him a controversial figure and intensified debate about conflicts of interest.
Some national health services and researchers have embraced a pragmatic approach. The U.K. National Health Service supports e-cigarettes as one option for cessation, and independent scientists such as Mike Cummings contend that safer nicotine alternatives deserve consideration for smokers who cannot quit by other means. Cummings and others claim that researchers who favor harm reduction have been marginalized and that suppressing discussion about alternatives amounts to anti-science censorship. At the same time, they acknowledge that industry funding muddies the evidence and public trust.
Opponents see echoes of past industry tactics that promoted “safer” cigarettes before later revelations exposed their harms. Tim McAfee, a former head of the U.S. CDC’s Office on Smoking and Health, has characterized promotions of supposedly safer cigarette replacements as deceptive and views aggressive e-cigarette marketing with deep skepticism.
Scientific uncertainty complicates policy choices. Products differ widely in design, nicotine delivery and emissions; some studies have identified metals and other toxicants linked to heating elements, while others find lower levels of certain harmful chemicals compared with conventional cigarettes. Long-term effects are still unknown, and WHO cautions against extrapolating results across diverse products.
At the heart of the dispute is a trade-off: do the potential benefits to current smokers outweigh the risks to non-smokers, particularly young people? And does the tobacco industry’s involvement render harm-reduction claims inherently suspect? Many experts call for rigorous, independent research and transparent debate to guide policy. Others argue that precautionary regulation is necessary now to prevent another generation from becoming nicotine-dependent.
As negotiators and health officials in Geneva weigh those questions, the outcome will shape global tobacco-control strategies for years to come — balancing potential short-term gains for individual smokers against broader population health risks and the possibility of renewed addiction among youth.